Esterification of
B16-F10
cell growth
melanoma
p-coumaric acid
tumor
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
12 Jan 2023
12 Jan 2023
Historique:
received:
23
08
2022
revised:
26
12
2022
accepted:
04
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Previous studies reported that p-coumaric acid modulates melanoma growth. Because the esterification of p-coumaric acid (p-CA) enhanced its activity as an antimelanogenic agent, we aimed to determine the antitumor potential of two derivatives, the ethyl and butyl esters, against the murine B16-F10 and the human SK-MEL-25 melanoma cells. Cell viability was determined in vitro by the lactate dehydrogenase release and violet crystal absorption assays. The cell proliferation rate and cell cycle behavior were determined by the colony formation assay and flow cytometry analysis. Although p-CA, at the concentration of 1 mM, failed to exert a significant antitumor activity, the ethyl and butyl ester derivatives caused substantial tumor cell death at doses < 1 mM. Despite a reduction in their direct cytotoxicity at minor doses, both products controlled the melanoma growth by arresting the cell cycle at the G0/G1 (B16-F10) or S/G2 (SK-MEL-25). Furthermore, the in vivo experiments showed that the butyl ester derivative suppressed the lung B16-F10 burden, compared to the p-CA-treated mice. Thus, the esterification of p-coumaric acid improved the control over the proliferation of murine and human melanoma cells and can be considered an approach for designing novel anticancer agents.
Identifiants
pubmed: 36672704
pii: biomedicines11010196
doi: 10.3390/biomedicines11010196
pmc: PMC9855326
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Coordenação de Aperfeicoamento de Pessoal de Nível Superior
ID : Finance code 001
Organisme : CNPq
ID : 308964/2019-5 and 306355/2018-3
Organisme : São Paulo Research Foundation (FAPESP)
ID : 2019/11490-5 2019/24028-8 2018/03918-2 2021/11200-7
Références
Eur J Immunol. 2017 Jun;47(6):946-953
pubmed: 28475283
J Pharm Biomed Anal. 2020 Jan 30;178:112922
pubmed: 31679843
Pharmacol Res. 2017 May;119:242-250
pubmed: 28212889
Value Health Reg Issues. 2019 Dec;20:47-50
pubmed: 30856543
Cold Spring Harb Protoc. 2016 Apr 01;2016(4):pdb.prot087379
pubmed: 27037069
Medicines (Basel). 2021 Apr 30;8(5):
pubmed: 33946188
Bioorg Chem. 2020 Oct;103:104108
pubmed: 32750608
Inflammation. 2013 Feb;36(1):169-76
pubmed: 22923003
Sci Rep. 2019 Jun 26;9(1):9280
pubmed: 31243305
Open Biol. 2021 Aug;11(8):210120
pubmed: 34375547
Immunology. 1999 May;97(1):159-65
pubmed: 10447727
Drug Chem Toxicol. 2017 Oct;40(4):416-424
pubmed: 27855523
Curr Protoc Cell Biol. 2001 May;Chapter 8:Unit 8.4
pubmed: 18228389
Cancer Res. 2017 May 15;77(10):2722-2734
pubmed: 28283655
Target Oncol. 2021 Sep;16(5):537-552
pubmed: 34554353
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Clin Oncol. 2005 Dec 20;23(36):9408-21
pubmed: 16361640
Rev Saude Publica. 2014 Dec;48(6):968-76
pubmed: 26039400
Toxicol Appl Pharmacol. 2016 Mar 15;295:56-67
pubmed: 26876618
Nat Rev Drug Discov. 2015 Feb;14(2):111-29
pubmed: 25614221
Cancer. 2020 Oct 15;126(20):4545-4552
pubmed: 32745271
Melanoma Res. 2020 Apr;30(2):136-146
pubmed: 30855528
J Am Chem Soc. 1971 May 5;93(9):2325-7
pubmed: 5553076
Nutr Cancer. 2011;63(4):611-22
pubmed: 21500097
Front Oncol. 2020 Oct 16;10:558414
pubmed: 33178586